Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum -- Ignore unavailable to you. Want to Upgrade?

To: cassie9 who wrote (4570)	2/14/2001 11:59:46 AM
From: Jenna	Respond to of 6445

SCRI, ADRX and CELG the biotechs I like here. These weren't even among today's upgrades. We are also long SHPGY earnings play

To: cassie9 who wrote (4570)	2/14/2001 12:03:41 PM
From: Jenna	Read Replies (2) \| Respond to of 6445

Avant! Market Gems Earnings Play from 13th February looking good for more possible upside. We are very circumspect and careful with our holds here. We won't take home junk. LTXX an early morning trigg still in strength but I wouldn't even hold that one. Holds we are taking are in the health sector, select pharmaceuticals and earnings plays that beat already and not guessing in others or taking blimps home. Reports 7th Consecutive Year of Record Growth Company Reports 28th Consecutive Quarter of Record Results FREMONT, Calif., Feb. 13 /PRNewswire/ -- Avant! Corporation (Nasdaq: AVNT - news) today reported record results for its year ended December 31, 2000. For the year, revenue was a record $358 million, an 18% increase over 1999 revenue of $304 million. Pro forma net earnings excluding merger, in-process research and development expenses and venture capital investment gains were a record $70.9 million, a 20% increase over 1999 net earnings of $59.0 million. Pro forma diluted earnings per share were also a record $1.77, a 20% increase over 1999 earnings per share of $1.48. Reported diluted earnings per share for the year including merger, in-process research and development expenses and venture capital investment gains were $2.07 compared to $1.42 last year. For the fourth quarter ended December 31, 2000, revenue was a record $93 million, a 14% increase over the fourth quarter revenue of $81 million last year. Pro forma net earnings excluding venture capital investment gains were a record $18.8 million, a 15% increase over fourth quarter 1999 net earnings of $16.3 million. Pro forma diluted earnings per share were also a record $0.47, a 15% increase over fourth quarter earnings per share of $0.41 last year. Reported diluted earnings per share for the quarter including venture capital investment gains were $0.57 compared to $0.51 last year.